P
XBI icon

&Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

&Partners’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.52M Buy
51,024
+15,834
+45% +$1.98M 0.03% 450
2025
Q4 		$4.29M Buy
35,190
+9,902
+39% +$1.14M 0.02% 552
2025
Q3 		$2.55M Buy
25,288
+1,722
+7% +$155K 0.02% 652
2025
Q2 		$1.95M Buy
23,566
+5,323
+29% +$425K 0.02% 678
2025
Q1 		$1.54M Sell
18,243
-104
-0.6% -$9.3K 0.02% 641
2024
Q4 		$1.69M Buy
18,347
+11,678
+175% +$1.13M 0.02% 567
2024
Q3 		$659K Buy
6,669
+730
+12% +$71.7K 0.01% 739
2024
Q2 		$551K Buy
5,939
+460
+8% +$41.2K 0.02% 506
2024
Q1 		$520K Hold
5,479
– – 0.07% 258
2023
Q4 		$489K Buy
5,479
+6
+0.1% +$446 0.12% 158
2023
Q3 		$400K Sell
5,473
-1,130
-17% -$90.3K 0.19% 99
2023
Q2 		$549K Hold
6,603
– – 0.25% 78
2023
Q1 		$503K Hold
6,603
– – 0.24% 85
2022
Q4 		$548K Sell
6,603
-100
-1% -$8.1K 0.27% 75
2022
Q3 		$532K Sell
6,703
-145
-2% -$12.2K 0.31% 75
2022
Q2 		$509K Buy
6,848
+473
+7% +$35.5K 0.29% 79
2022
Q1 		$573K Sell
6,375
-50
-0.8% -$4.62K 0.32% 74
2021
Q4 		$719K Buy
6,425
+500
+8% +$60.3K 0.43% 56
2021
Q3 		$745K Sell
5,925
-110
-2% -$14.2K 0.47% 53
2021
Q2 		$817K Buy
6,035
+220
+4% +$28.9K 0.53% 42
2021
Q1 		$789K Hold
5,815
– – 0.57% 44
2020
Q4 		$819K Sell
5,815
-225
-4% -$28.8K 0.69% 41
2020
Q3 		$673K Hold
6,040
– – 0.68% 43
2020
Q2 		$676K Sell
6,040
-200
-3% -$19.7K 0.82% 35
2020
Q1 		$483K Hold
6,240
– – 0.75% 40
2019
Q4 		$593K Hold
6,240
– – 0.71% 47
2019
Q3 		$476K Sell
6,240
-375
-6% -$31.2K 0.62% 59
2019
Q2 		$580K Hold
6,615
– – 0.8% 41
2019
Q1 		$599K Buy
6,615
+60
+0.9% +$5.1K 0.86% 35
2018
Q4 		$461K Buy
+6,555
New +$528K 0.77% 37

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

&Partners's XBI Position: Q1 2026 in Review

&Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 45% in Q1 2026, buying an estimated $1.98M and bringing the position to 51,024 shares worth $6.52M. The position accounts for 0.03% of the portfolio, ranked #450.

&Partners first reported a position in XBI in Q4 2018 and has held it in 30 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • &Partners held 51,024 shares of State Street SPDR S&P Biotech ETF worth $6.52M as of Q1 2026.
  • &Partners bought 15,834 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.98M.
  • State Street SPDR S&P Biotech ETF made up 0.03% of &Partners's portfolio in Q1 2026, its #450 holding.
  • &Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 30 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.